Molecular Formula | C15H14FN3O2 |
Molar Mass | 287.29 |
Density | 1.382±0.06 g/cm3(Predicted) |
Boling Point | 449.9±45.0 °C(Predicted) |
Solubility | Soluble in DMSO |
pKa | 12.13±0.70(Predicted) |
Storage Condition | -20℃ |
Use | BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. The selectivity of BRD3308 to HDAC3 is 23 times higher than that of HDAC1 (IC50 is 1.26 μM) or HDAC2 (IC50 is 1.34 μM). BRD3308 inhibits pancreatic β-cell apoptosis induced by inflammatory cytokines or glycolipid toxic stress and increases functional insulin release. BRD3308 can also activate HIV-1 transcription and destroy HIV-1 latency. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.481 ml | 17.404 ml | 34.808 ml |
5 mM | 0.696 ml | 3.481 ml | 6.962 ml |
10 mM | 0.348 ml | 1.74 ml | 3.481 ml |
5 mM | 0.07 ml | 0.348 ml | 0.696 ml |
biological activity | BRD3308 is a potent, highly selective inhibitor of HDAC3, the IC50 values for HDAC1 and HDAC2 were 54 nM, 1.26 μm and 1.34 μm, respectively. BRD3308 can activate HIV-1 transcription. BRD3308 inhibits pancreatic β-cell apoptosis induced by inflammatory cytokines (glycolipid toxicity stress) and increases the release of functional insulin. |
Target | Value |
HDAC3 (Cell-free assay) | 54 nM |
HDAC1 (Cell-free assay) | 1.26 μM |
HDAC2 (Cell-free assay) | 1.34 μM |